This CPB is revised state that leuprolide, goserelin, histrelin, triptorelin and degarelix are considered medically necessary for men with prostate cancer (not limited to advanced prostate cancer). This CPB is revised to state that leuprolide is considered medically necessary for epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer when criteria are met. This CPB is revised to state the leuprolide and goserelin are considered medically necessary for men and premenopausal women with hormone-receptor positive breast cancer. This CPB is revised to state that triptorelin is considered medically necessary for prostate cancer. These policy revisions are supported by guidelines from the National Comprehensive Cancer Network. This CPB is revised to remove abarelix from the policy statement, as this product has been withdrawn from the market.